Abstract
The major stages of chemical carcinogenesis have been deduced over the past ∼50 years, primarily from animal model studies (and particularly from studies using the mouse skin model); these stages are termed initiation, promotion, and progression. Tumor initiation begins when DNA in a cell or population of target cells is damaged by exposure to exogenous or endogenous carcinogens leading to mutations in critical target genes. The responsiveness of initiated cells to their microenvironment gives them a growth advantage relative to normal cells under certain conditions. In the classic two-stage chemical carcinogenesis system in the mouse skin, a low dose of a carcinogen such as 7,12-dimethylbenz(a)anthracene induces a mutation in Hras1 that does not give rise to tumors over the lifespan of the mouse unless a tumor promoter, such as TPA, is repeatedly applied. The tumor promotion stage is characterized by selective clonal expansion of the initiated cells, a result of the altered expression of genes whose products are associated with hyperproliferation, tissue remodeling, and inflammation. During tumor progression, preneoplastic cells undergo malignant transformation through a process of selection that is facilitated by progressive genomic instability and altered gene expression. While the processes involved in each stage of experimental chemical carcinogenesis also appear to be involved in human carcinogenesis, the temporal nature of initiation, promotion, and progression events is more complex. In addition, multiple mutational events are involved in the formation of human tumors. Genetic background and nutritional status can dramatically affect susceptibility to a carcinogenic exposure in both experimental animals and humans. An understanding of the multistage nature of carcinogenesis has led to the discovery of mechanism-based inhibitors that target events associated with specific stages. Further study of the cellular, biochemical, and molecular mechanisms associated carcinogenesis induced by chemicals and other types of carcinogens will lead to identification of effective strategies for cancer prevention.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abel, E.L., Angel, J.M, et al. (2009). Nat Protoc 4: 1350–1362.
Abel, E.L., Angel, J.M, et al. (2010). J Natl Cancer Inst 102: 1663–1675.
Affara, N.I., Schanbacher, B.L., et al. (2004). Anticancer Res 24: 2773–2781.
Affara, N.I., Trempus, C.S., et al. (2006). Anticancer Res 26: 2805–2820.
Alam, A., Khan, N., et al. (2002). Pharmacol Res 46: 557–564.
Aldaz, C.M. and Conti, C.J. (1989). Carcinog Compr Surv 11: 227–242.
Aldaz, C.M., Conti, C.J., et al. (1987). Proc Natl Acad Sci USA 84: 2029–2032.
Aldaz, C., Trono, M.D., et al. (1989). Mol Carcinog 2: 22–26.
Alin, P., Danielson, U.H., et al. (1985). FEBS Lett 179: 267–270.
Angel, J.M. and DiGiovanni, J. (1999). Prog Exp Tumor Res 35: 143–157.
Angel, J.M. and Richie, E.R. (2002). Mol Carcinog 33: 105–112.
Angel, J.M., Morizot, D.C., et al. (1993). Mol Carcinog 7: 151–156.
Angel, J.M., Beltran, L., et al. (1997). Mol Carcinog 20: 162–167.
Angel, J.M., Popova, N., et al. (2000). Mol Carcinog 27: 47–54.
Angel, J.M., Caballero, M., et al. (2001). Mol Carcinog 32: 169–175.
Angel, J.M., Caballero, M., et al. (2003). Cancer Res 63: 2747–2751.
Bailleul, B., Surani, M.A., et al. (1990). Cell 62: 697–708.
Balmain, A., Ramsden, M., et al. (1984). Nature 307: 658–660.
Bargmann, C., Hung, M., et al. (1986). Nature 319: 226–230.
Bassi, D.E., Lopez De Cicco, R., et al. (2005). Cancer Res 65: 7310–7319.
Bennett, L.M., Winkler, M.L., et al. (1993). Proc Am Assoc Cancer Res 34: 144.
Bickenbach, J.R. and Mackenzie, I.C. (1984). J Invest Dermatol 82: 618–622.
Bilodeau, J.F. and Mirault, M.E. (1999). Int J Cancer 80: 863–867.
Birt, D.F., Pelling, J.C., et al. (1991). Cancer Res 51: 1851–1854.
Birt, D.F., Pinch, H.J., et al. (1993). Cancer Res 53: 27–31.
Blanpain, C., Lowry, W.E., et al. (2004). Cell 118: 635–648.
Boutwell, R. (1964). Prog Exp Tumor Res 4: 207–250.
Boutwell, R. (1974). CRC Crit Rev Toxicol 2: 419–443.
Boutwell, R. (1976). Cancer Res 36: 2631–2635.
Braakhuis, B.J., Tabor, M.P., et al. (2003). Cancer Res 63: 1727–1730.
Brabletz, T., Jung, A., et al. (2005). Nat Rev Cancer 5: 744–749.
Brown, K., Buchmann, A., et al. (1990). Proc Natl Acad Sci USA 87: 538–542.
Budunova, I.V., Perez, P., et al. (1999). Oncogene 18: 7423–7431.
Calle, E.E., Rodriguez, C., et al. (2003). N Engl J Med 348: 1625–1638.
Camandola, S., Poli, G., et al. (2000). J Neurochem 74: 159–168.
Cano, A., Perez-Moreno, M.A., et al. (2000). Nat Cell Biol 2: 76–83.
Casanova, M.L., Larcher, F., et al. (2002). Cancer Res 62: 3402–3407.
Caulin, C., Bauluz, C., et al. (1993). Exp Cell Res 204: 11–21.
Chan, K.S., Sano, S., et al. (2004). J Clin Invest 114: 720–728.
Chan, K.S., Sano, S., et al. (2008). Oncogene 27: 1087–1094.
Cheng, J.Z., Singhal, S.S., et al. (1999). Arch Biochem Biophys 372: 29–36.
Citri, A., Skaria, K.B., et al. (2003). Exp Cell Res 284: 54–65.
Clark, W.H., Jr., From, L., et al. (1969). Cancer Res 29: 705–727.
Coghlan, L.G., Gimenez-Conti, I., et al. (2000). Carcinogenesis 21: 641–646.
Conti, C.J. (1994). The mouse skin as a model for chemical carcinogenesis. In: J.P. Sundberg (ed) Handbook of Mouse Mutations with Skin and Hair Abnormalities. Boca Raton, FL, CRC Press: 39–55.
Conti, C.J., Aldaz, C.M., et al. (1986). Carcinogenesis 7: 1845–1848.
Cooper, S.J. and Bowden, G.T. (2007). Curr Cancer Drug Targets 7: 325–334.
Cope, F., Wagner, F., et al. (1988). Mol Carcinog 1: 116–124.
Cormier, R.T., Hong, K.H., et al. (1997). Nat Genet 17: 88–91.
Cotsarelis, G. (2006). J Invest Dermatol 126: 1459–1468.
Demant, P. (1992). Semin Cancer Biol 3: 159–166.
Dianzani, M.U., Barrera, G., et al. (1999). Acta Biochim Pol 46: 61–75.
Dietrich, W.F., Lander, E.S., et al. (1993). Cell 75: 631–639.
DiGiovanni, J. (1989). Metabolism of polycyclic aromatic bydrocarbons and phorbol esters by mouse skin: relevance to mechanism of action and trans-species/strain carcinogenesis. In: T.J. Slaga, D. Stevenson and A.J.P. Klein-Szanto et al. (eds) Progress in Clinical and Biological Research Skin Carcinogenesis: Research Directions Mechanisms and Human Relevance. New York, Alan R. Liss. Vol. 298: 167–199.
DiGiovanni, J. (1992). Pharmacol Ther 54: 63–128.
DiGiovannni, J. (1994). Multistage skin carcinogenesis. In: J. Ward and M.P. Waalkes (eds) Carcinogenesis, Target Organ Toxicology Series. New York, Raven Press: 265–299.
DiGiovanni, J. (1997). Genetic determinants of cancer susceptibility. In: G.T. Bowden and S.M. Fischer (eds) Comprehensive Toxicology, Carcinogens and Anticarcinogens. New York, Pergamon Press Vol. 10: 425–451.
DiGiovanni, J., Imamoto, A., et al. (1992). Carcinogenesis 13: 525–531.
DiGiovanni, J., Bol, D.K., et al. (2000). Cancer Res 60: 1561–1570.
Dominey, A.M., Wang, X.J., et al. (1993). Cell Growth Differ 4: 1071–1082.
El-Abaseri, T.B., Putta, S., et al. (2006). Carcinogenesis 27: 225–231.
Engelman, J.A., Luo, J., et al. (2006). Nat Rev Genet 7: 606–619.
Esterbauer, H., Schaur, R.J., et al. (1991). Free Radic Biol Med 11: 81–128.
Ewart-Toland, A., Briassouli, P., et al. (2003). Nat Genet 34: 403–412.
Fearon, E.R. and Vogelstein, B. (1990). Cell 61: 759–767.
Fijneman, R.J., de Vries, S.S., et al. (1996). Nat Genet 14: 465–467.
Finch, J.S., Albino, H.E., et al. (1996). Carcinogenesis 17: 2551–2557.
Fischer, S.M. (1997). Cellular and molecular mechanisms of tumor promotion. In: G.T. Bowden and S.M. Fischer (eds) Comprehensive Toxicology. New York, Elsevier Science Ltd. Vol. 12: 349–381.
Fischer, S.M. and DiGiovanni, J. (1995). Cancer Bull 47: 456–463.
Fischer, S.M., Baldwin, J.K., et al. (1986). Carcinogenesis 7: 915–918.
Fischer, S., Baldwin, J., et al. (1987a). Carcinogenesis 8: 1521–1524.
Fischer, S.M., O’Connell, J.F., et al. (1987b). Carcinogenesis 8: 421–424.
Fischer, S., Baldwin, J., et al. (1988). Cancer Res 48: 658–664.
Fujiwara, K., Igarashi, J., et al. (2007). BMC Genet 8: 39.
Furstenberger, G., Rogers, M., et al. (1989). Int J Cancer 43: 915–921.
Gariboldi, M., Manenti, G., et al. (1993). Cancer Res 53: 209–211.
Garte, S., Edinger, F., et al. (1985). Cancer Lett 29: 215–221.
Gerdes, M.J. and Yuspa, S.H. (2005). Stem Cell Rev 1: 225–231.
Gilbert, D.J., Neumann, P.E., et al. (1993). J Virol 67: 2083–2090.
Gimenez-Conti, I.B., Bianchi, A.B., et al. (1992). Cancer Res 52: 3432–3435.
Glick, A.B. and Yuspa, S.H. (2005). Semin Cancer Biol 15: 75–83.
Graus-Porta, D., Beerli, R.R., et al. (1997). EMBO J 16: 1647–1655.
Guo, Y., Zhao, J., et al. (1999). Mol Carcinog 26: 32–36.
Hahn, W.C. and Weinberg, R.A. (2002). Nat Rev Cancer 2: 331–341.
Hammer, A., Ferro, M., et al. (1997). Free Radic Biol Med 23: 26–33.
Han, C.Y., Lim, S.C., et al. (2008). Cancer Sci 99: 502–509.
Hanahan, D. and Weinberg, R.A. (2000). Cell 100: 57–70.
Hanigan, M.H., Kemp, C.J. et al. (1988). Carcinogenesis 9: 885–890.
Hedley, A.A., Ogden, C.L., et al. (2004). JAMA 291: 2847–2850.
Hennings, H., Glick, A.B., et al. (1993). Carcinogenesis 14: 2353–2358.
Hennings, H., Lowry, D.T., et al. (1997). Mol Carcinog 20: 143–150.
Hirabayashi, N., Naito, M., et al. (1988). Carcinogenesis 9: 2215–2220.
Hirabayashi, N., Warren, B., et al. (1990). Mol Carcinog 3: 171–180.
Hubatsch, I., Ridderstrom, M., et al. (1998). Biochem J 330: 175–179.
Hursting, S.D., Lavigne, J.A., et al. (2003). Annu Rev Med 54: 131–152.
Hursting, S.D., Nunez, N.P., et al. (2005). Mutat Res 576: 80–92.
Imamoto, A., Beltran, L.M., et al. (1991). Mol Carcinog 4: 52–60.
Imamoto, A., Beltran, L.M., et al. (1992). Carcinogenesis 13: 177–182.
Imamoto, A., Wang, X.-J., et al. (1993). Carcinogenesis 14: 719–724.
Ise, K., Nakamura, K., et al. (2000). Oncogene 19: 2951–2956.
Jacoby, R.F., Hohman, C., et al. (1994). Genomics 22: 381–387.
Jang, M. and Pezzuto, J.M. (1998). Cancer Lett 134: 81–89.
Jhappan, C., Takayama, H., et al. (1994). Cell Growth Differ 5: 385–394.
Jiang, W., Zhu, Z., et al. (2002). Cancer Res 62: 5280–5287.
Kang, Y. and Massague, J. (2004). Cell 118: 277–279.
Kangsamaksin, T., Park, H.J., et al. (2007). Mol Carcinog 46: 579–584.
Karunagaran, D., Tzahar, E., et al. (1996). EMBO J 15: 254–264.
Kataoka, K., Kim, D.J., et al. (2008). Carcinogenesis 29: 1108–1114.
Katiyar, S.K., Korman, N.J., et al. (1997). J Natl Cancer Inst 89: 556–566.
Kelloff, G.J., Lippman, S.M., et al. (2006). Clin Cancer Res 12: 3661–3697.
Kemp, C.J. (2005). Semin Cancer Biol 15: 460–473.
Kiguchi, K., Beltran, L.M., et al. (1995). Mol Carcinog 12: 225–235.
Kiguchi, K., Beltran, L., et al. (1997). J Invest Dermatol 108: 784–791.
Kiguchi, K., Beltran, L., et al. (1998). Mol Carcinog 22: 73–83.
Kiguchi, K., Bol, D., et al. (2000). Oncogene 19: 4243–4254.
Kiguchi, K., Kitamura, T., et al. (2010). Cancer Prev Res 3: 940–952.
Kim, D.J., Chan, K.S., et al. (2007). Mol Carcinog 46: 725–731.
Kim, D.J., Kataoka, K., et al. (2009). Cancer Res 69: 7587–7594.
Kinzler, K.W. and Vogelstein, B. (1996). Cell 87: 159–170.
Klein, E.A. (2005). Nat Clin Pract Urol 2: 24–31.
Klein-Szanto, A.J.P. (1989). Pathology of human and experimental skin tumors. In: C.J. Conti, T.J. Slaga and A.J.P. Klein-Szanto (eds) Skin Tumors: Experimental and Clinical Aspects. New York City, Raven Press: 19–53.
Klein-Szanto, A.J. and Slaga, T.J. (1982). J Invest Dermatol 79: 30–34.
Knudson, A.G. (1993). Proc Natl Acad Sci USA 90: 10914–10921.
Koorstra, J.B., Hustinx, S.R., et al. (2008). Pancreatology 8: 110–125.
Koster, M.I., Lu, S.L., et al. (2006). Cancer Res 66: 3981–3986.
Lahiri-Chatterjee, M., Katiyar, S.K., et al. (1999). Cancer Res 59: 622–632.
Lazo, P.A. (1999). Br J Cancer 80: 2008–2018.
Lee, G.H. and Drinkwater, N.R. (1995). Carcinogenesis 16: 1993–1996.
Lee, G.H., Bennett, L.M., et al. (1995). Genetics 139: 387–395.
Lewis, J.G. and Adams, D.O. (1986). Cancer Res 46: 5696–5700.
Lippman, S.M. and Hawk, E.T. (2009). Cancer Res 69: 5269–5284.
Lippman, S.M. and Hong, W.K. (2002). Cancer Res 62: 5119–5125.
Liu, W., Kato, M., et al. (2000). J Cell Sci 113: 635–641.
Llorens, A., Rodrigo, I., et al. (1998). Lab Invest 78: 1131–1142.
Luo, J., Manning, B.D., et al. (2003). Cancer Cell 4: 257–262.
MacPhee, M., Chepenik, K.P., et al. (1995). Cell 81: 957–966.
Madson, J.G., Lynch, D.T., et al. (2006). Am J Pathol 169: 1402–1414.
Madson, J.G., Lynch, D.T., et al. (2009). Am J Pathol 174: 2357–2366.
Mao, J.H., Saunier, E.F., et al. (2006). Proc Natl Acad Sci USA 103: 8125–8130.
Miller, S.J., Wei, Z.G., et al. (1993). J Invest Dermatol 101: 591–594.
Mills, K. and Smart, R. (1989). Carcinogenesis 10: 833–838.
Mock, B.A., Krall, M.M., et al. (1993). Proc Natl Acad Sci USA 90: 9499–9503.
Mock, B.A., Lowry, D.T., et al. (1998). Carcinogenesis 19: 1109–1115.
Moen, C.J., Snoek, M., et al. (1992). Oncogene 7: 563–566.
Moen, C.J., Groot, P.C., et al. (1996). Proc Natl Acad Sci USA 93: 1082–1086.
Moore, T., Beltran, L., et al. (2008a). Cancer Prev Res 1: 65–76.
Moore, T., Carbajal, S., et al. (2008b). Cancer Res 68: 3680–3688.
Morris, R.J. (2004). Differentiation 72: 381–386.
Morris, R.J., Fischer, S.M., et al. (1985). J Invest Dermatol 84: 277–281.
Morris, R.J., Fischer, S.M., et al. (1986). Cancer Res 46: 3061–3066.
Moser, A.R., Pitot, H.C., et al. (1990). Science 247: 322–324.
Mukhtar, H., Mercurio, M.G., Agarwal, R. (1995). Murine skin carcinogenesis: relevance to humans. In: H. Mukhtar (ed) Skin Cancer: Mechanisms and Human Relevance. Boca Raton, FL, CRC Press.
Munshi, H.G. and Stack, M.S. (2006). Cancer Metastasis Rev 25: 45–56.
Nagase, H., Bryson, S., et al. (1995). Nat Genet 10: 424–429.
Nagase, H., Mao, J.H., et al. (1999). Proc Natl Acad Sci USA 96: 15032–15037.
Naito, M. and DiGiovanni, J. (1989a). Carcinog Compr Surv 11: 187–212.
Naito, M. and DiGiovanni, J. (1989b). Genetic background and development of skin tumors. In: C.J. Conti, A.J.P. Klein-Szanto, and T.J. Slaga (eds) Carcinogenesis, Skin Tumors, Experimental and Clinical Aspects. New York, NY, Raven Press: 187–212.
Naito, M., Chenicek, K.J., et al. (1988). Carcinogenesis 9: 639–645.
Navarro, P., Gomez, M., et al. (1991). J Cell Biol 115: 517–533.
Negre-Salvayre, A., Vieira, O., et al. (2003). Mol Aspects Med 24: 251–261.
Nelson, M.A., Futscher, B.W., et al. (1992). Proc Natl Acad Sci USA 89: 6398–6402.
Nicholson, R.I., Hutcheson, I.R., et al. (2001). Endocr Relat Cancer 8: 175–182.
Olmeda, D., Jorda, M., et al. (2007). Oncogene 26: 1862–1874.
Panchal, H., Wansbury, O., et al. (2007). BMC Dev Biol 7: 105.
Papathoma, A.S., Zoumpourlis, V., et al. (2001). Mol Carcinog 31: 74–82.
Paradisi, L., Panagini, C., et al. (1985). Chem Biol Interact 53: 209–217.
Park, Y.G., Zhao, X., et al. (2005). Nat Genet 37: 1055–1062.
Park, E., Zhu, F., et al. (2007). Cancer Res 67: 9158–9168.
Pashko, L.L. and Schwartz, A.G. (1992). Carcinogenesis 13: 1925–1928.
Patel, A.C., Nunez, N.P., et al. (2004). J Nutr 134: 3394S–3398S.
Peinado, H., Olmeda, D., et al. (2007). Nat Rev Cancer 7: 415–428.
Peissel, B., Zaffaroni, D., et al. (2001). Mamm Genome 12: 291–294.
Perchellet, E.M. and Perchellet, J.P. (1989). Cancer Res 49: 6193–6201.
Perchellet, J.P., Perchellet, E.M., et al. (1985). Cancer Lett 26: 283–293.
Perchellet, J.P., Abney, N.L., et al. (1987). Cancer Res 47: 6302–6309.
Perchellet, J.-P. and Perchellet, E., et al. (1995). Oxidant stress and multistage skin carcinogenesis. In: H. Mukhtar (ed) Skin Cancer: Mechanisms and Human Relevance. Boca Raton, FL, CRC Press: 145–196.
Perez-Ordonez, B., Beauchemin, M., et al. (2006). J Clin Pathol 59: 445–453.
Peto, J. (1980). Predisposition to cancer. In: J. Cairns, J.L. Lyon and M. Skolnick (eds) Cancer Incidence in Defined Populations (Banbury Report 4). Cold Spring Harbor, Cold Spring Harbor Laboratory Press: 203–213.
Philipp, J., Vo, K., et al. (1999). Oncogene 18: 4689–4698.
Pierceall, W.E., Kripke, M.L., et al. (1992). Cancer Res 52: 3946–3951.
Pinkas-Kramarski, R., Soussan, L., et al. (1996). EMBO J 15: 2452–2467.
Pino, M.S. and Chung, D.C. (2010). Gastroenterology 138: 2059–2072.
Pitot, H.C. and Dragan, Y.P. (1991). FASEB J 5: 2280–2286.
Ponder, B.A. (1990). Trends Genet 6: 213–218.
Prickett, T.D., Agrawal, N.S., et al. (2009). Nat Genet 41: 1127–1132.
Rehman, I., Lowry, D.T., et al. (2000). Mol Carcinog 27: 298–307.
Reiners, J.J., Jr., Nesnow, S., et al. (1984). Carcinogenesis 5: 301–307.
Reiners, J.J., Jr., Thai, G., et al. (1991). Carcinogenesis 12: 2337–2343.
Rho, O., Beltran, L.M., et al. (1994). Mol Carcinog 11: 19–28.
Richie, E.R., Schumacher, A., et al. (2002). Oncogene 21: 299–306.
Riggs, P.K., Angel, J.M., et al. (2005). Mol Carcinog 44: 122–136.
Rinaldi, M., Barrera, G., et al. (2000). Biochem Biophys Res Commun 272: 75–80.
Rossi, M.A., Fidale, F., et al. (1990). Biochem Pharmacol 39: 1715–1719.
Ruef, J., Rao, G.N., et al. (1998). Circulation 97: 1071–1078.
Ruggeri, B., Caamano, J., et al. (1991). Cancer Res 51: 6615–6621.
Rundhaug, J.E., Fuscher, S.M., Bowden, G.T. (1997). Tumor promoters and models of promotion. In: G.T. Bowden and S.M. Fischer (eds) Comprehensive Toxicology. Oxford, UK, Pergamon. Vol. 12.
Saez, E., Rutberg, S.E., et al. (1995). Cell 82: 721–732.
Segditsas, S., Rowan, A.J., et al. (2009). Oncogene 28: 146–155.
Segrelles, C., Ruiz, S., et al. (2002). Oncogene 21: 53–64.
Segrelles, C., Moral, M., et al. (2006). Oncogene 25: 1174–1185.
Segrelles, C., Lu, J., et al. (2007). Cancer Res 67: 10879–10888.
Shaw, R.J. and Cantley, L.C. (2006). Nature 441: 424–430.
Shih, C., Padhy, L., et al. (1981). Nature 290: 261–264.
Slaga, T.J. (1984). Mechanisms involved in two-stage carcinogenesis in mouse skin. In: T.J. Slaga (ed) Mechanisms of Tumor Promotion. Boca Raton, FL, CRC Press. Vol. II: 1–16.
Slaga, T.J. and DiGiovanni, J. (1984). Inhibition of carcinogenesis. In: C.E. Searle (ed) Chemical Carcinogens. ACS Monograph. Vol. II: 1279–1321.
Slaga, T.J., Klein-Szanto, A.J., et al. (1981). Science 213: 1023–1025.
Slaga, T.J., Fischer, S.M., et al. (1982). J Cell Biochem 18: 99–119.
Slaga, T.J., Budunova, I.V., et al. (1996). J Investig Dermatol Symp Proc 1(2): 151–156.
Soh, Y., Jeong, K.S., et al. (2000). Mol Pharmacol 58: 535–541.
Solanki, V., Rana, R.S., et al. (1981). Carcinogenesis 2: 1141-1146.
Song, B.J., Soh, Y., et al. (2001). Chem Biol Interact 130–132: 943–954.
Stern, M.C., Gimenez-Conti, I.B., et al. (1995). Carcinogenesis 16: 1947–1953.
Stern, M.C., Benavides, F., et al. (2002). Mol Carcinog 35: 13–20.
Stewart, J.W., Koehler, K., et al. (2005). Carcinogenesis 26: 1077–1084.
Stoll, S.W., Kansra, S., et al. (2001). Neoplasia 3: 339–350.
Su, L.K., Kinzler, K.W., et al. (1992). Science 256: 668–670.
Sugimura, T. (1992). Science 258: 603–607.
Thiery, J.P. (2002). Nat Rev Cancer 2: 442–454.
Trempus, C.S., Morris, R.J., et al. (2003). J Invest Dermatol 120: 501–511.
Trempus, C.S., Morris, R.J., et al. (2007). Cancer Res 67: 4173–4181.
Uchida, K., Shiraishi, M., et al. (1999). J Biol Chem 274: 2234–2242.
Ullrich, A., Coussens, L., et al. (1984). Nature 309: 418–424.
Ullrich, O., Siems, W.G., et al. (1996). Biochem J 315: 705–708.
van Wezel, T., Stassen, A.P., et al. (1996). Nat Genet 14: 468–470.
Vassar, R., Hutton, M., et al. (1992). Mol Cell Biol 12: 4643–4653.
Vulimiri, S.V. and DiGiovanni, J. (1999). Carcinogenesis. In: R.E. Pollack (ed) Manual of Clinical Oncology. New York, Wiley-Liss: 19–43.
Walker, C., Goldsworthy, T.L., et al. (1992). Science 255: 1693–1695.
Wang, X.J., Greenhalgh, D.A., et al. (1994). Mol Carcinog 10: 15–22.
Wei, H. and Frenkel, K., (1993). Carcinogenesis 14: 1195–1201.
Wei, L., Wei, H., et al. (1993). Carcinogenesis 14: 841–847.
Wheldrake, J., Marshall, J., et al. (1982). Carcinogenesis 3: 805–807.
Wilker, E., Lu, J., et al. (2005). Mol Carcinog 44: 137–145.
William, W.N., Jr., Heymach, J.V., et al. (2009). Nat Rev Drug Discov 8: 213–225.
Wistuba, II., Behrens, C., et al. (1999). Oncogene 18: 643–650.
Woodworth, C.D., Michael, E., et al. (2004). Carcinogenesis 25: 1771–1778.
Xian, W., Kiguchi, K., et al. (1995). Cell Growth Differ 6: 1447–1455.
Xian, W., Rosenberg, M.P., et al. (1997). Oncogene 14: 1435–1444.
Yakar, S., Nunez, N.P., et al. (2006). Endocrinology 147: 5826–5834.
Yang, J., Mani, S.A., et al. (2006). Cancer Res 66: 4549–4552.
Yao, D., Alexander, C.L., et al. (2006). Cancer Res 66: 1302–1312.
Yarden, Y. and Sliwkowski, M.X. (2001). Nat Rev Mol Cell Biol 2: 127–137.
Yates, R.A., Nanney, L.B., et al. (1991). Int J Dermatol 30: 687–694.
Yeung, R.S., Xiao, G.H., et al. (1994). Proc Natl Acad Sci USA 91: 11413–11416.
Youngren, K.K., Coveney, D., et al. (2005). Nature 435: 360–364.
Yuspa, S.H. (1994). Cancer Res 54: 1178–1189.
Yuspa, S.H. (1998). J Dermatol Sci 17: 1–7.
Yuspa, S.H. (2000). Carcinogenesis 21: 341–344.
Zhang, S.L., DuBois, W., et al. (2001). Mol Cell Biol 21: 310–318.
Zhang, S., Qian, X., et al. (2003). Oncogene 22: 2285–2295.
Zhao, J., Sharma, Y., et al. (1999). Mol Carcinog 26: 321–333.
Zhao, J., Lahiri-Chatterjee, M., et al. (2000). Carcinogenesis 21: 811–816.
Zhao, Y., Xue, Y., et al. (2001). Cancer Res 61: 6082–6088.
Zhaorigetu, S., Yanaka, N., et al. (2003). Oncol Rep 10: 537–543.
Zhou, Q., Zhao, J., et al. (1997). J Biol Chem 272: 18240–18244.
Zhu, Z., Jiang, W., et al. (1998). Carcinogenesis 19: 2101–2106.
Zi, X., Mukhtar, H., et al. (1997). Biochem Biophys Res Commun 239: 334–339.
Zimniak, P., Singhal, S.S., et al. (1994). J Biol Chem 269: 992–1000.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Abel, E.L., DiGiovanni, J. (2011). Multistage Carcinogenesis. In: Penning, T. (eds) Chemical Carcinogenesis. Current Cancer Research. Humana Press. https://doi.org/10.1007/978-1-61737-995-6_2
Download citation
DOI: https://doi.org/10.1007/978-1-61737-995-6_2
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61737-994-9
Online ISBN: 978-1-61737-995-6
eBook Packages: MedicineMedicine (R0)